BGM0504
Intervention1 paper2 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
- Human trial1
Outcomes
2Waist circumference
downin humans1
1 study
Waist circumference
downin humans1
BGM0504 decreases waist circumference in humans (-8.88 cm, -12.71 cm, -14.38 cm, and -1.03 cm, respectively).
Human trialoverweight or obesity without diabetes24 weeksn = 120
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial · Diabetes, obesity & metabolism · 17 Sep 2026
Body weight
downin humans1
1 study
Body weight
downin humans1
BGM0504 decreases body weight in humans (-10.68%, -16.07%, -18.33%, and 0.13% with BGM0504 5 mg, 10 mg, 15 mg, and placebo).
Human trialoverweight or obesity without diabetes24 weeksn = 120
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial · Diabetes, obesity & metabolism · 17 Sep 2026